Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сложности диагностики интестинальной Т-клеточной лимфомы. Клиническое наблюдение
Сложности диагностики интестинальной Т-клеточной лимфомы. Клиническое наблюдение
Гадаев И.Ю., Ершов В.И., Ковригина А.М., Соколова И.Я., Тащян О.В., Мингалимов М.А., Антюфеева О.Н., Буданова Д.А., Мнацаканян М.Г., Бочкарникова О.В., Нагорная Д.С. Сложности диагностики интестинальной Т-клеточной лимфомы. Клиническое наблюдение. Терапевтический архив. 2023;95(2):180–186. DOI: 10.26442/00403660.2023.02.202060
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье приведено описание редкого диагноза мономорфной эпителиотропной интестинальной Т-клеточной лимфомы (MEITL) ввиду завуалированности ее рядом «масок» энтеропатий. Детальный анализ всех клинико-морфологических и иммуногистохимических данных позволил установить правильный диагноз. Выявленная патология относится к крайне редко встречающейся в практике даже у специалистов гематологов/онкогематологов. В статье продемонстрированы как основные этапы сложной диагностики, так и попытка терапии этой агрессивной формы кишечной лимфомы.
Ключевые слова: T- и NK-клеточные лимфопролиферативные заболевания желудочно-кишечного тракта, энтеропатия-ассоциированная Т-клеточная лимфома, мономорфная эпителиотропная кишечная Т-клеточная лимфома
Keywords: T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract, enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma
Ключевые слова: T- и NK-клеточные лимфопролиферативные заболевания желудочно-кишечного тракта, энтеропатия-ассоциированная Т-клеточная лимфома, мономорфная эпителиотропная кишечная Т-клеточная лимфома
________________________________________________
Keywords: T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract, enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma
Полный текст
Список литературы
1. Chan JKC, Fukuyama M. Haematolymphoidtumours of the digestive system. In: WHO Classification of Tumours Editorial Board. WHO classification of tumours of the digestive system. 5th ed. Vol 1. Lyon: IARC, 2019.
2. van Vliet С, Spagnolo DV. T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. Pathology. 2020;52(1):128-41. DOI:10.1016/j.pathol.2019.10.001
3. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148-55. DOI:10.1182/blood-2011-02-335216
4. Jaffe ES, Chott A, Ott G, et al. Intestinal T-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. SH Swerdlow, E Campo, NL Harris, et al. Revised. 4th ed. Lyon: IARC, 2017.
5. Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447-52. DOI:10.1182/blood-2010-08-302737
6. Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134:986-91. DOI:10.1182/blood.2019001443
7. Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631-7. DOI:10.1182/blood-2010-06-290650
8. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795-803. DOI:10.1200/JCO.2000.18.4.795
9. Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87:663-8. DOI:10.1002/ajh.23213
10. Tan SY, Chuang SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27:1688-96. DOI:10.1038/leu.2013.41
11. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664-70. DOI:10.1182/blood-2009-07-231324
12. Silano M, Volta U, De Vincenzi A, Dessi MDM. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53:972-6. DOI:10.1007/s10620-007-9952-8
13. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern Med. 2013;159:169-75.
DOI:10.7326/0003-4819-159-3-201308060-00006
14. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology. 2015;66:112-36. DOI:10.1111/his.12596
15. Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137:1227-31.
DOI:10.5858/arpa.2013-0242-CR
16. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377-84. DOI:10.1016/j.dld.2012.12.001
17. Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig R. 2016;11:504-13. DOI:10.1007/s11899-016-0357-7
18. Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30:2245-7. DOI:10.1038/leu.2016.178
19. Attygalle AD, Cabeçadas J, Gaulard P, et al. Peripheral T-cell and NKcell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171-99. DOI:10.1111/his.12251
20. Kikuma K, Yamada K, Nakamura S, et al. Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2014;45:1276-84. DOI:10.1016/j.humpath.2013.10.038
21. Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35:1557-69. DOI:10.1097/PAS.0b013e318222dfcd
22. Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma – a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41:1231-7. DOI:10.1016/j.humpath.2009.11.020
23. Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28:1286-96. DOI:10.1038/modpathol.2015.85
24. Isaacson PGT, Bhagat G. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas. In: Jaffe ES, Arber DA, Campo E, et al., ed. Hematopathology. 2nd ed. Philadelphia: Elsevier, 2017.
25. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483-90. DOI:10.1016/S0002-9440(10)65736-7
26. Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371-86. DOI:10.1084/jem.20160894
27. Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated Tcell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. DOI:10.1038/ncomms12602
28. Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. E Clinical Medicine. 2020;27:100549.
29. Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192:415. DOI:10.1111/bjh.17116
30. de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191:386-9. DOI:10.1111/bjh.17066
31. Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. Leuk Lymphoma. 2020:1-19. DOI:10.1080/10428194.2020
32. Perini GF, Fischer T, Gaiolla RD, et al. Hemoterapia e TerapiaCelular (ABHH) How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42:103-10. DOI:10.1016/j.htct.2020.04.002
33. Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192:1100-5. DOI:10.1111/bjh.17266
2. van Vliet С, Spagnolo DV. T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. Pathology. 2020;52(1):128-41. DOI:10.1016/j.pathol.2019.10.001
3. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148-55. DOI:10.1182/blood-2011-02-335216
4. Jaffe ES, Chott A, Ott G, et al. Intestinal T-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. SH Swerdlow, E Campo, NL Harris, et al. Revised. 4th ed. Lyon: IARC, 2017.
5. Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447-52. DOI:10.1182/blood-2010-08-302737
6. Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134:986-91. DOI:10.1182/blood.2019001443
7. Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631-7. DOI:10.1182/blood-2010-06-290650
8. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795-803. DOI:10.1200/JCO.2000.18.4.795
9. Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87:663-8. DOI:10.1002/ajh.23213
10. Tan SY, Chuang SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27:1688-96. DOI:10.1038/leu.2013.41
11. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664-70. DOI:10.1182/blood-2009-07-231324
12. Silano M, Volta U, De Vincenzi A, Dessi MDM. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53:972-6. DOI:10.1007/s10620-007-9952-8
13. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern Med. 2013;159:169-75.
DOI:10.7326/0003-4819-159-3-201308060-00006
14. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology. 2015;66:112-36. DOI:10.1111/his.12596
15. Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137:1227-31.
DOI:10.5858/arpa.2013-0242-CR
16. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377-84. DOI:10.1016/j.dld.2012.12.001
17. Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig R. 2016;11:504-13. DOI:10.1007/s11899-016-0357-7
18. Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30:2245-7. DOI:10.1038/leu.2016.178
19. Attygalle AD, Cabeçadas J, Gaulard P, et al. Peripheral T-cell and NKcell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171-99. DOI:10.1111/his.12251
20. Kikuma K, Yamada K, Nakamura S, et al. Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2014;45:1276-84. DOI:10.1016/j.humpath.2013.10.038
21. Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35:1557-69. DOI:10.1097/PAS.0b013e318222dfcd
22. Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma – a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41:1231-7. DOI:10.1016/j.humpath.2009.11.020
23. Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28:1286-96. DOI:10.1038/modpathol.2015.85
24. Isaacson PGT, Bhagat G. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas. In: Jaffe ES, Arber DA, Campo E, et al., ed. Hematopathology. 2nd ed. Philadelphia: Elsevier, 2017.
25. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483-90. DOI:10.1016/S0002-9440(10)65736-7
26. Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371-86. DOI:10.1084/jem.20160894
27. Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated Tcell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. DOI:10.1038/ncomms12602
28. Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. E Clinical Medicine. 2020;27:100549.
29. Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192:415. DOI:10.1111/bjh.17116
30. de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191:386-9. DOI:10.1111/bjh.17066
31. Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. Leuk Lymphoma. 2020:1-19. DOI:10.1080/10428194.2020
32. Perini GF, Fischer T, Gaiolla RD, et al. Hemoterapia e TerapiaCelular (ABHH) How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42:103-10. DOI:10.1016/j.htct.2020.04.002
33. Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192:1100-5. DOI:10.1111/bjh.17266
2. van Vliet С, Spagnolo DV. T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. Pathology. 2020;52(1):128-41. DOI:10.1016/j.pathol.2019.10.001
3. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148-55. DOI:10.1182/blood-2011-02-335216
4. Jaffe ES, Chott A, Ott G, et al. Intestinal T-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. SH Swerdlow, E Campo, NL Harris, et al. Revised. 4th ed. Lyon: IARC, 2017.
5. Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447-52. DOI:10.1182/blood-2010-08-302737
6. Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134:986-91. DOI:10.1182/blood.2019001443
7. Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631-7. DOI:10.1182/blood-2010-06-290650
8. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795-803. DOI:10.1200/JCO.2000.18.4.795
9. Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87:663-8. DOI:10.1002/ajh.23213
10. Tan SY, Chuang SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27:1688-96. DOI:10.1038/leu.2013.41
11. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664-70. DOI:10.1182/blood-2009-07-231324
12. Silano M, Volta U, De Vincenzi A, Dessi MDM. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53:972-6. DOI:10.1007/s10620-007-9952-8
13. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern Med. 2013;159:169-75.
DOI:10.7326/0003-4819-159-3-201308060-00006
14. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology. 2015;66:112-36. DOI:10.1111/his.12596
15. Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137:1227-31.
DOI:10.5858/arpa.2013-0242-CR
16. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377-84. DOI:10.1016/j.dld.2012.12.001
17. Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig R. 2016;11:504-13. DOI:10.1007/s11899-016-0357-7
18. Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30:2245-7. DOI:10.1038/leu.2016.178
19. Attygalle AD, Cabeçadas J, Gaulard P, et al. Peripheral T-cell and NKcell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171-99. DOI:10.1111/his.12251
20. Kikuma K, Yamada K, Nakamura S, et al. Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2014;45:1276-84. DOI:10.1016/j.humpath.2013.10.038
21. Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35:1557-69. DOI:10.1097/PAS.0b013e318222dfcd
22. Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma – a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41:1231-7. DOI:10.1016/j.humpath.2009.11.020
23. Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28:1286-96. DOI:10.1038/modpathol.2015.85
24. Isaacson PGT, Bhagat G. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas. In: Jaffe ES, Arber DA, Campo E, et al., ed. Hematopathology. 2nd ed. Philadelphia: Elsevier, 2017.
25. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483-90. DOI:10.1016/S0002-9440(10)65736-7
26. Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371-86. DOI:10.1084/jem.20160894
27. Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated Tcell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. DOI:10.1038/ncomms12602
28. Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. E Clinical Medicine. 2020;27:100549.
29. Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192:415. DOI:10.1111/bjh.17116
30. de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191:386-9. DOI:10.1111/bjh.17066
31. Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. Leuk Lymphoma. 2020:1-19. DOI:10.1080/10428194.2020
32. Perini GF, Fischer T, Gaiolla RD, et al. Hemoterapia e TerapiaCelular (ABHH) How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42:103-10. DOI:10.1016/j.htct.2020.04.002
33. Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192:1100-5. DOI:10.1111/bjh.17266
________________________________________________
2. van Vliet С, Spagnolo DV. T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. Pathology. 2020;52(1):128-41. DOI:10.1016/j.pathol.2019.10.001
3. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148-55. DOI:10.1182/blood-2011-02-335216
4. Jaffe ES, Chott A, Ott G, et al. Intestinal T-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. SH Swerdlow, E Campo, NL Harris, et al. Revised. 4th ed. Lyon: IARC, 2017.
5. Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447-52. DOI:10.1182/blood-2010-08-302737
6. Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134:986-91. DOI:10.1182/blood.2019001443
7. Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631-7. DOI:10.1182/blood-2010-06-290650
8. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795-803. DOI:10.1200/JCO.2000.18.4.795
9. Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87:663-8. DOI:10.1002/ajh.23213
10. Tan SY, Chuang SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27:1688-96. DOI:10.1038/leu.2013.41
11. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664-70. DOI:10.1182/blood-2009-07-231324
12. Silano M, Volta U, De Vincenzi A, Dessi MDM. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53:972-6. DOI:10.1007/s10620-007-9952-8
13. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern Med. 2013;159:169-75.
DOI:10.7326/0003-4819-159-3-201308060-00006
14. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology. 2015;66:112-36. DOI:10.1111/his.12596
15. Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137:1227-31.
DOI:10.5858/arpa.2013-0242-CR
16. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377-84. DOI:10.1016/j.dld.2012.12.001
17. Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig R. 2016;11:504-13. DOI:10.1007/s11899-016-0357-7
18. Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30:2245-7. DOI:10.1038/leu.2016.178
19. Attygalle AD, Cabeçadas J, Gaulard P, et al. Peripheral T-cell and NKcell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171-99. DOI:10.1111/his.12251
20. Kikuma K, Yamada K, Nakamura S, et al. Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2014;45:1276-84. DOI:10.1016/j.humpath.2013.10.038
21. Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35:1557-69. DOI:10.1097/PAS.0b013e318222dfcd
22. Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma – a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41:1231-7. DOI:10.1016/j.humpath.2009.11.020
23. Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28:1286-96. DOI:10.1038/modpathol.2015.85
24. Isaacson PGT, Bhagat G. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas. In: Jaffe ES, Arber DA, Campo E, et al., ed. Hematopathology. 2nd ed. Philadelphia: Elsevier, 2017.
25. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483-90. DOI:10.1016/S0002-9440(10)65736-7
26. Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371-86. DOI:10.1084/jem.20160894
27. Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated Tcell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. DOI:10.1038/ncomms12602
28. Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. E Clinical Medicine. 2020;27:100549.
29. Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192:415. DOI:10.1111/bjh.17116
30. de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191:386-9. DOI:10.1111/bjh.17066
31. Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. Leuk Lymphoma. 2020:1-19. DOI:10.1080/10428194.2020
32. Perini GF, Fischer T, Gaiolla RD, et al. Hemoterapia e TerapiaCelular (ABHH) How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42:103-10. DOI:10.1016/j.htct.2020.04.002
33. Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192:1100-5. DOI:10.1111/bjh.17266
Авторы
И.Ю. Гадаев*1, В.И. Ершов1, А.М. Ковригина2, И.Я. Соколова1, О.В. Тащян1, М.А. Мингалимов1, О.Н. Антюфеева1, Д.А. Буданова1, М.Г. Мнацаканян1, О.В. Бочкарникова1, Д.С. Нагорная1
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
*doktor-gai@yandex.ru
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 National Medical Research Center for Hematology, Moscow, Russia
*doktor-gai@yandex.ru
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
*doktor-gai@yandex.ru
________________________________________________
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 National Medical Research Center for Hematology, Moscow, Russia
*doktor-gai@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.